Brief: Enodia Therapeutics Announces Research Collaboration And License Agreement With Pfizer To Develop Sec61-Targeting Small Molecules
13/10/2026 12:09
BRIEF-Enodia Therapeutics Announces Research Collaboration And License Agreement With Pfizer To Develop Sec61-Targeting Small Molecules Oct 13 (Reuters) - Pfizer Inc. PFE.N:
ENODIA THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH PFIZER TO DEVELOP SEC61-TARGETING SMALL MOLECULES
ENODIA THERAPEUTICS: PFIZER WILL BE RESPONSIBLE FOR ALL CLINICAL, MANUFACTURING, REGULATORY AND COMMERCIAL ACTIVITIES
ENODIA THERAPEUTICS: WILL CONDUCT DISCOVERY ACTIVITIES TO SCREEN, OPTIMIZE, DEVELOP SEC61 INHIBITOR CANDIDATES AGAINST MULTIPLE COLLABORATION TARGETS
ENODIA THERAPEUTICS : DEAL WITH PFIZER HAS TOTAL POTENTIAL VALUE OVER $500M INCLUDING UPFRONT, MILESTONES AND ROYALTIES
Source text: ID:nBwDw8lXa
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma